Insider Trading Alert - DexCom And 4 Others Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 3, 2013, 116 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $30.21 to $14,999,997.60.

Highlighted Stocks Traded by Insiders:

DexCom (DXCM) - FREE Research Report

Gregg Terrance H who is Ceo at DexCom sold 9,000 shares at $27.99 on Oct. 3, 2013. Following this transaction, the Ceo owned 750,889 shares meaning that the stake was reduced by 1.18% with the 9,000 share transaction.

The shares most recently traded at $28.82, up $0.83, or 2.88% since the insider transaction. Historical insider transactions for DexCom go as follows:

  • 24-Week # shares sold: 18,633

The average volume for DexCom has been 530,100 shares per day over the past 30 days. DexCom has a market cap of $2.0 billion and is part of the health care sector and health services industry. Shares are up 106.11% year to date as of the close of trading on Thursday.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. Currently there are 8 analysts that rate DexCom a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXCM - FREE

TheStreet Quant Ratings rates DexCom as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full DexCom Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Medicines (MDCO) - FREE Research Report

Meanwell Clive who is Chairman & CEO at Medicines sold 7,500 shares at $33.45 on Oct. 3, 2013. Following this transaction, the Chairman & CEO owned 327,773 shares meaning that the stake was reduced by 2.24% with the 7,500 share transaction.

The shares most recently traded at $33.17, down $0.28, or 0.84% since the insider transaction. Historical insider transactions for Medicines go as follows:

  • 4-Week # shares sold: 24,394
  • 12-Week # shares sold: 39,394
  • 24-Week # shares sold: 57,103

The average volume for Medicines has been 945,200 shares per day over the past 30 days. Medicines has a market cap of $1.8 billion and is part of the health care sector and drugs industry. Shares are up 33.58% year to date as of the close of trading on Thursday.

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company has a P/E ratio of 48.5. Currently there are 5 analysts that rate Medicines a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDCO - FREE

TheStreet Quant Ratings rates Medicines as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Medicines Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

J.M. Smucker (SJM) - FREE Research Report

Denman John W who is Vice President, Controller at J.M. Smucker sold 200 shares at $105.10 on Oct. 3, 2013. Following this transaction, the Vice President, Controller owned 18,849 shares meaning that the stake was reduced by 1.05% with the 200 share transaction.

The shares most recently traded at $106.14, up $1.04, or 0.98% since the insider transaction. Historical insider transactions for J.M. Smucker go as follows:

  • 4-Week # shares sold: 1,300
  • 12-Week # shares sold: 13,657
  • 24-Week # shares sold: 39,297

The average volume for J.M. Smucker has been 500,600 shares per day over the past 30 days. J.M. Smucker has a market cap of $11.2 billion and is part of the consumer goods sector and food & beverage industry. Shares are up 23.36% year to date as of the close of trading on Thursday.

The J. M. Smucker Company engages in manufacturing and marketing branded food products worldwide. The company operates through three segments: U.S. Retail Coffee; U.S. Retail Consumer Foods; and International, Foodservice, and Natural Foods. The stock currently has a dividend yield of 2.18%. The company has a P/E ratio of 20.5. Currently there are 8 analysts that rate J.M. Smucker a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SJM - FREE

TheStreet Quant Ratings rates J.M. Smucker as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, increase in net income, expanding profit margins, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full J.M. Smucker Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Orbitz Worldwide (OWW) - FREE Research Report

Orton Christopher who is Pres., Orbitz & Cheaptickets at Orbitz Worldwide sold 3,629 shares at $9.52 on Oct. 3, 2013. Following this transaction, the Pres., Orbitz & Cheaptickets owned 66,907 shares meaning that the stake was reduced by 5.14% with the 3,629 share transaction.

The shares most recently traded at $9.55, up $0.03, or 0.32% since the insider transaction. Historical insider transactions for Orbitz Worldwide go as follows:

  • 4-Week # shares sold: 85,972
  • 12-Week # shares sold: 8.3 million
  • 24-Week # shares sold: 8.8 million

The average volume for Orbitz Worldwide has been 1.3 million shares per day over the past 30 days. Orbitz Worldwide has a market cap of $1.1 billion and is part of the services sector and leisure industry. Shares are up 263.6% year to date as of the close of trading on Thursday.

Orbitz Worldwide, Inc. operates as an online travel company worldwide. It enables leisure and business travelers to research, plan, and book a range of travel products and services. Currently there are 2 analysts that rate Orbitz Worldwide a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OWW - FREE

TheStreet Quant Ratings rates Orbitz Worldwide as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity and feeble growth in its earnings per share. Get the full Orbitz Worldwide Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

First Solar (FSLR) - FREE Research Report

Garabedian Raffi who is Chief Technology Officer at First Solar sold 262 shares at $40.39 on Oct. 3, 2013. Following this transaction, the Chief Technology Officer owned 807 shares meaning that the stake was reduced by 24.51% with the 262 share transaction.

The shares most recently traded at $43.17, up $2.78, or 6.44% since the insider transaction. Historical insider transactions for First Solar go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 2,362
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 2,362
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 16,810

The average volume for First Solar has been 4.2 million shares per day over the past 30 days. First Solar has a market cap of $3.8 billion and is part of the technology sector and electronics industry. Shares are up 26.52% year to date as of the close of trading on Thursday.

First Solar, Inc. provides solar energy solutions. It operates in two segments, Components and Systems. The Components segment engages in the design, manufacture, and sale of solar modules that convert sunlight into electricity. The company has a P/E ratio of 10.2. Currently there are 2 analysts that rate First Solar a buy, 2 analysts rate it a sell, and 13 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FSLR - FREE

TheStreet Quant Ratings rates First Solar as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and feeble growth in the company's earnings per share. Get the full First Solar Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Stocks Trade Lower as Optimism Wanes Over China Trade Talks

Stocks Trade Lower as Optimism Wanes Over China Trade Talks

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know